BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients


Autoria(s): CARVALHO, D. D. De; BINATO, R.; PEREIRA, W. O.; LEROY, J. M. G.; COLASSANTI, M. D.; PROTO-SIQUEIRA, R.; BUENO-DA-SILVA, A. E. B.; ZAGO, M. A.; ZANICHELLI, M. A.; ABDELHAY, E.; CASTRO, F. A.; JACYSYN, J. F.; AMARANTE-MENDES, G. P.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2011

Resumo

Tumor necrosis factor-related apoptosis-inducing ligand-TNFSF10 (TRAIL), a member of the TNF-alpha family and a death receptor ligand, was shown to selectively kill tumor cells. Not surprisingly, TRAIL is downregulated in a variety of tumor cells, including BCR-ABL-positive leukemia. Although we know much about the molecular basis of TRAIL-mediated cell killing, the mechanism responsible for TRAIL inhibition in tumors remains elusive because (a) TRAIL can be regulated by retinoic acid (RA); (b) the tumor antigen preferentially expressed antigen of melanoma (PRAME) was shown to inhibit transcription of RA receptor target genes through the polycomb protein, enhancer of zeste homolog 2 (EZH2); and (c) we have found that TRAIL is inversely correlated with BCR-ABL in chronic myeloid leukemia (CML) patients. Thus, we decided to investigate the association of PRAME, EZH2 and TRAIL in BCR-ABL-positive leukemia. Here, we demonstrate that PRAME, but not EZH2, is upregulated in BCR-ABL cells and is associated with the progression of disease in CML patients. There is a positive correlation between PRAME and BCR-ABL and an inverse correlation between PRAME and TRAIL in these patients. Importantly, knocking down PRAME or EZH2 by RNA interference in a BCR-ABL-positive cell line restores TRAIL expression. Moreover, there is an enrichment of EZH2 binding on the promoter region of TRAIL in a CML cell line. This binding is lost after PRAME knockdown. Finally, knocking down PRAME or EZH2, and consequently induction of TRAIL expression, enhances Imatinib sensibility. Taken together, our data reveal a novel regulatory mechanism responsible for lowering TRAIL expression and provide the basis of alternative targets for combined therapeutic strategies for CML. Oncogene (2011) 30, 223-233; doi:10.1038/onc.2010.409; published online 13 September 2010

Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP-Brazil)

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

FAPESP

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Brazilian Research Council (CNPq-Brazil)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Identificador

ONCOGENE, v.30, n.2, p.223-233, 2011

0950-9232

http://producao.usp.br/handle/BDPI/28251

10.1038/onc.2010.409

http://dx.doi.org/10.1038/onc.2010.409

Idioma(s)

eng

Publicador

NATURE PUBLISHING GROUP

Relação

Oncogene

Direitos

restrictedAccess

Copyright NATURE PUBLISHING GROUP

Palavras-Chave #PRAME #TRAIL #TNFSF10 #EZH2 #CML #BCR-ABL #APOPTOSIS-INDUCING LIGAND #CHRONIC MYELOID-LEUKEMIA #GENE-EXPRESSION PROFILES #DOWN-REGULATION #IN-VIVO #DEFICIENT MICE #ANTIGEN PRAME #TNF-FAMILY #CELLS #DEATH #Biochemistry & Molecular Biology #Oncology #Cell Biology #Genetics & Heredity
Tipo

article

original article

publishedVersion